HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074

Philip J. Palumbo, Yinfeng Zhang, Jessica M. Fogel, Xu Guo, William Clarke, Autumn Breaud, Paul Richardson, Estelle Piwowar-Manning, Stephen Hart, Erica L. Hamilton, Ngo T.K. Hoa, Mariya Liulchuk, Latifah Anandari, Tran Viet Ha, Kostyantyn Dumchev, Zubairi Djoerban, Irving Hoffman, Brett Hanscom, William C. Miller, Susan H. Eshleman

Research output: Contribution to journalArticle

Abstract

Background Persons who inject drugs (PWID) have high HIV incidence and prevalence, and may have limited access to antiretroviral therapy (ART) in some settings. We evaluated HIV drug resistance in PWID in a randomized clinical trial (HPTN 074). The study intervention included ART at any CD4 cell count with enhanced support for ART and substance use treatment. Methods HPTN 074 enrolled HIV-infected PWID (index participants) with viral loads .1,000 copies/ mL and their HIV-uninfected injection-network partners in Indonesia, Ukraine, and Vietnam; the study limited enrollment of people who reported being on ART. HIV drug resistance testing and antiretroviral (ARV) drug testing were performed using samples collected from index participants at study enrollment. Results Fifty-four (12.0%) of 449 participants had HIV drug resistance; 29 (53.7%) of the 54 participants had multi-class resistance. Prevalence of resistance varied by study site and was associated with self-report of prior or current ART, detection of ARV drugs, and a history of incarceration. Resistance was detected in 10 (5.6%) of 177 newly diagnosed participants. Participants with resistance at enrollment were less likely to be virally suppressed after 52 weeks of follow-up, independent of study arm. Conclusions In HPTN 074, many of the enrolled index participants had HIV drug resistance and more than half of those had multi-class resistance. Some newly-diagnosed participants had resistance, suggesting that they may have been infected with drug-resistant HIV strains. Behavioral and geographic factors were associated with baseline resistance. Baseline resistance was associated with reduced viral suppression during study follow-up. These findings indicate the need for enhanced HIV care in this high-risk population to achieve sustained viral suppression on ART.

Original languageEnglish (US)
Article numbere0223829
JournalPloS one
Volume14
Issue number10
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074'. Together they form a unique fingerprint.

  • Cite this

    Palumbo, P. J., Zhang, Y., Fogel, J. M., Guo, X., Clarke, W., Breaud, A., Richardson, P., Piwowar-Manning, E., Hart, S., Hamilton, E. L., Hoa, N. T. K., Liulchuk, M., Anandari, L., Ha, T. V., Dumchev, K., Djoerban, Z., Hoffman, I., Hanscom, B., Miller, W. C., & Eshleman, S. H. (2019). HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. PloS one, 14(10), [e0223829]. https://doi.org/10.1371/journal.pone.0223829